Register NOW for the FREE IMF Virtual Myeloma Community Workshop

Dr. Mikhael will be kicking off the program with introductions and welcome and then we will be covering the following topics:

• Should all high-risk smoldering patients be treated?
• Is transplant still the standard of care for all eligible patients?
• Should most patients only have maintenance therapy for 2 years?

Dr. Richter will argue "yes" for each topic above and Dr. Hansen will argue "no" for each topic. 

Additional Resources:

Download the IMF's Multiple Myeloma Informational Booklets:

Download IMF publications (https://www.myeloma.org/cancer-information-series)

What Is a Clinical Trial? (https://www.myeloma.org/clinical-trials)

*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:

• CANOVA Clinical Trial Fact Sheet (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax%20CANOVA_M13-494_NCT03539744_a3.pdf)
  clinicaltrials.gov Identifier: NCT03539744
• Phase II Relapsed or Refractory Venetoclax Trial  (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-338_NCT02899052_a3.pdf)
  clinicaltrials.gov Identifier: NCT02899052
• Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib  (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-654_NCT03314181_a3.pdf)
  clinicaltrials.gov Identifier: NCT03314181

Workshop Sponsors:

With Support From: Abbvie, Amgen, BMS, GSK, Johnson & Johnson, Johnson & Johnson w Legend, Karyopharm, Kite, and Pfizer

(The IMF is not responsible for content provided by the links below and you may be subject to the Privacy Policy and Terms & Conditions of the destination site(s).)

	Cervino Study (https://cervinostudy.com/home/) CLINICAL TRIAL FACT SHEET (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2024-11/CTFS_ABBV-383_NCT06158841_a5_single.pdf) ClinicalTrials.gov ID: NCT06158841 (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2024-11/CTFS_ABBV-383_NCT06158841_a5_single.pdf) HOJA INFORMATIVA DEL ENSAYO CLÍNICO (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2024-11/CTFS_ABBV-383_NCT06158841_ES_a5-02_single.pdf) ID de ClinicalTrials.gov: NCT06158841 (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2024-11/CTFS_ABBV-383_NCT06158841_ES_a5-02_single.pdf)
	Kyprolis Patient Resources (https://www.kyprolis.com/patient-resources) Kyprolis Patient Brochure (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2026-08/Kyprolis_USA-171-81833_ASC-18324_Digital_links.pdf)
	Revlimid Treatment Overview brochure (https://media.revlimid.com/wp-content/uploads/2020/01/US-REV-19-0673-REVLIMID-Treatment-Overview-Brochure.pdf) POM My Disease and Treatment (pomalyst.com) (https://www.pomalyst.com/assets/commercial/us/pomalystdtc/en/pdf/POM-My-Disease-and-Treatment-2204-US-2100028.pdf) Harness your power to fight MM with ABECMA® (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-06/BMS%20for%20Table%20Top%20-%20Abecma%20Patient%20Brochure.pdf)
	www.blenrep.com (https://www.blenrep.com) Together with BLENREP Homepage | TogetherWithGSK.com (https://www.togetherwithgsk.com/blenrep/patient/)
	Tecvayli® (https://www.tecvayli.com/) Darzalex® (https://www.darzalex.com/) Talvey (https://www.talvey.com/) Patient Support Program | CARVYKTI® (ciltacabtagene autoleucel) (https://www.carvykti.com/patient-support-program/)
	KaryForward, Patient Support Program (https://www.karyforward.com/assets/pdf/English_KF_Patient_Flyer_Sept2021.pdf) KaryForward, Patient Support Program, Espanol (https://www.karyforward.com/assets/pdf/Spanish_KF_Patient_Flyer_Feb2022_final.pdf) Patient and Caregiver Brochure (https://www.xpovio.com/content/pdf/mm/XPOVIO_Patient_and_Caregiver_Brochure.pdf) Treatment Experience Guide (https://www.xpovio.com/content/pdf/mm/Patient-Treatment-Experience-3.23.pdf)
	ELREXFIO® (elranatamab-bcmm) Info for Patients | Safety Info (https://www.elrexfio.com/) Your Guide to Understanding Elrexfio (https://www.elrexfio.com/assets/pdfs/your-guide-to-understanding-elrexfio.pdf) ELREXFIO® (elranatamab-bcmm) Personalized Patient Support | Safety Info (https://www.elrexfio.com/patient-support)